is retatrutide a glp-1 drug Weight Loss Results:Trial Data and FDA Status Medscape | The investigational triple

However, individual results vary, and the best medication for any person depends on their unique medical profile

In the REDEFINE 2 trial in patients with type 2 diabetes, it achieved 13.7% weight loss and brought 73.5% of patients to HbAc 6.5% ( [141] )

Much more research is needed before doctors can determine whether these medications can actually reduce inflammation or relieve symptoms inside the joints

Currently, multiple phase 3 trials with oral semaglutide and orforglipron are ongoing for different populations (NCT05803421), while another oral GLP-1 RA (CT-996) is in early phase clinical trials (Table 1)

They slow stomach emptying, reduce appetite, and may cause side effects such as nausea, vomiting, or diarrhea, all of which can contribute to dehydration